Drug Trial Radar · NCT02926898
A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome
Last checked: Nov 19, 2026Latest source record: Nov 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Jan 27, 2017
Primary completion
Jun 5, 2018
Study completion Jun 5, 2018
Sponsor
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 6, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of ZX008 (fenfluramine hydrochloride) when added to adjunctive antiepileptic stiripentol treatment in children and young adults with Dravet syndrome.
Conditions
- Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride)Drug
ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. \*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base.
Matching PlaceboDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) PeriodTime frame: 15 weeks (combined Titration + Maintenance Period)
Locations
28 sites in 7 countries. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Children'S Hospital Colorado
Aurora, Colorado
Ann & Robert H. Lurie Children'S Hospital of Chicago
Chicago, Illinois
Children'S Hospital of Michigan
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
Bc Children'S Hospital Division of Neurology
Vancouver, British Columbia, Canada
Chu Sainte-Justine Hospital Neurology Clinic
Montreal, Quebec, Canada
Chu Amiens Picardie Service de Neurologie Pédiatrique
Amiens, France
Chu de Bordeaux Hôpital Des Enfants
Bordeaux, France
HÔPITAL FEMME-MÈRE-ENFANT Hôpital Service de Neurologie Pédiatrique
Bron, France
Chru de Lille Hôpital Roger Salengro
Lille, France
Hôpital de La Timone, Service de Neuro-Métabolisme Pédiatrique
Marseille, France
Hôpital Necker-Enfants Malades
Paris, France
Hôpital Robert-Debré
Paris, France
Chu de Toulouse - Hôpital Des Enfants
Toulouse, France
Hôpital D'Enfants Chur de Nancy
Vandœuvre-lès-Nancy, France
Krankenhaus Mara, Epilepsie-Zentrum Bethel
Bielefeld, Germany
Universitätsklinikum Schleswig-Holstein, Klinik Für Neuropädiatrie
Kiel, Germany
Kleinwachau Sächsisches Epilepsiezentrum Radeberg
Radeberg, Germany
Epilepsiecentrum Kempenhaeghe
Heeze, Netherlands
Stichting Epilepsie Instellingen Nederland
Zwolle, Netherlands
Hospital Sant Joan de Déu Barcelona
Barcelona, Spain
Hospital Ruber Internacional-Servicio de Neurología
Madrid, Spain
Cliníca Universidad de Navarra Nidad de Neuropediatría
Pamplona, Spain
Alder Hey Children'S Nhs Foundation Trust, Littlewood'S Neurosciences Unit
Liverpool, United Kingdom
Evelina London Children'S Hospital, Paediatric Neurosciences
London, United Kingdom
Great Ormond Street Hospital For Children Nhs Foundation Trust
London, United Kingdom
Royal Hospital For Children, Queen Elizabeth University, Institute of Neurosciences Hospital
Glasgow, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.